Xingqi Pharmaceutical released its 2026 interim report, with total operating revenue of 1.401 billion yuan and net profit attributable to the parent company of 430 million yuan. Net cash inflow from operating activities was 393 million yuan, the asset-liability ratio was 21.15%, gross margin was 82.29%, return on equity was 19.90%, and diluted earnings per share was 1.20 yuan. Total asset turnover was 0.53 times, and inventory turnover fell 8.08% year on year. The number of shareholders was 48,500, and the top ten shareholders held 33.55% of total share capital.
Shenyang Xingqi Pharmaceutical Co LtdInterim report shows strong net profit of 430 million yuan and high gross margin.